Study of Efficacy and Safety of Xolair® (Omalizumab) in Chinese Patients With Chronic Spontaneous Urticaria
Status:
Completed
Trial end date:
2019-09-24
Target enrollment:
Participant gender:
Summary
The purpose of this study was to demonstrate the efficacy and safety of omalizumab, compared
with placebo, as an add-on to H1 antihistamines (H1AH) therapy in adult patients suffering
from Chronic Spontaneous Urticaria (CSU) who remained symptomatic despite H1AH therapy.